摘要
Acute kidney injury (AKI) affects approximately 15% of hospitalized patients globally, with significant morbidity and mortality largely attributed to disrupted immuno-parenchymal crosstalk that intensifies tissue damage. Conventional treatments predominantly manage symptoms rather than fundamentally addressing the critical interactions between immune cells and renal parenchymal cells essential for effective kidney repair. Recent advances suggest that immuno-parenchymal crosstalk can significantly influence epigenetic landscapes within these cells, presenting a novel therapeutic target for renal diseases. This study introduces an innovative antioxidant nanotherapy, formulated through a co-deposition modification strategy employing MXene, polydopamine (PDA), and hyaluronic acid (HA). The developed nanotherapeutics specifically targets CD44-expressing inflammatory immune cells, thereby substantially enhancing immuno-parenchymal crosstalk, optimizing cellular metabolism, reducing apoptosis in renal tubular cells, and correlating with improved renal outcomes. Our findings demonstrate that targeting immuno-parenchymal crosstalk with antioxidant nanotherapeutics effectively optimize epigenetic reprogramming in renal tubular cells. By strategically targeting and modulating these pivotal cellular interactions, this research marks a significant advance in AKI treatment, advocating a shift towards more targeted and effective therapeutic approaches in renal medicine.
危险品化学品经营许可证(带存储)